Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Shares Purchased by Zhang Financial LLC

Zhang Financial LLC lifted its stake in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX - Free Report) by 14.8% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 4,631 shares of the pharmaceutical company's stock after purchasing an additional 596 shares during the quarter. Zhang Financial LLC's holdings in Vertex Pharmaceuticals were worth $1,865,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Northwest Investment Counselors LLC acquired a new position in Vertex Pharmaceuticals during the 3rd quarter worth approximately $25,000. Highline Wealth Partners LLC purchased a new stake in shares of Vertex Pharmaceuticals in the third quarter valued at approximately $27,000. Dunhill Financial LLC grew its holdings in Vertex Pharmaceuticals by 70.6% during the third quarter. Dunhill Financial LLC now owns 58 shares of the pharmaceutical company's stock worth $27,000 after acquiring an additional 24 shares during the period. Legacy Investment Solutions LLC acquired a new stake in Vertex Pharmaceuticals in the third quarter valued at $33,000. Finally, Truvestments Capital LLC purchased a new stake in shares of Vertex Pharmaceuticals during the 3rd quarter worth $35,000. 90.96% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of brokerages have recently issued reports on VRTX. Morgan Stanley increased their price target on shares of Vertex Pharmaceuticals from $473.00 to $476.00 and gave the company an "equal weight" rating in a report on Tuesday, November 5th. Needham & Company LLC reiterated a "hold" rating on shares of Vertex Pharmaceuticals in a research report on Friday, December 20th. StockNews.com lowered Vertex Pharmaceuticals from a "strong-buy" rating to a "buy" rating in a research note on Thursday, November 21st. Bank of America dropped their price objective on Vertex Pharmaceuticals from $545.00 to $522.00 and set a "buy" rating for the company in a research note on Thursday, December 19th. Finally, Wells Fargo & Company dropped their price target on Vertex Pharmaceuticals from $555.00 to $460.00 and set an "overweight" rating for the company in a research report on Friday, January 10th. Three research analysts have rated the stock with a sell rating, ten have given a hold rating, eighteen have issued a buy rating and one has assigned a strong buy rating to the company's stock. According to data from MarketBeat, Vertex Pharmaceuticals has a consensus rating of "Moderate Buy" and a consensus price target of $490.38.

Vertex Pharmaceuticals Trading Up 1.2 %

Shares of VRTX traded up $5.04 during mid-day trading on Monday, reaching $422.00. The company had a trading volume of 1,771,827 shares, compared to its average volume of 1,811,179. Vertex Pharmaceuticals Incorporated has a fifty-two week low of $377.85 and a fifty-two week high of $519.88. The firm has a fifty day simple moving average of $440.94 and a 200-day simple moving average of $466.06. The stock has a market cap of $108.68 billion, a price-to-earnings ratio of -212.06, a price-to-earnings-growth ratio of 2.11 and a beta of 0.40. The company has a current ratio of 2.47, a quick ratio of 2.20 and a debt-to-equity ratio of 0.01.

Vertex Pharmaceuticals (NASDAQ:VRTX - Get Free Report) last issued its earnings results on Monday, November 4th. The pharmaceutical company reported $4.38 earnings per share for the quarter, beating analysts' consensus estimates of $3.61 by $0.77. The firm had revenue of $2.77 billion for the quarter, compared to analysts' expectations of $2.69 billion. Vertex Pharmaceuticals had a negative return on equity of 1.91% and a negative net margin of 4.52%. The firm's revenue for the quarter was up 11.6% compared to the same quarter last year. During the same quarter last year, the firm earned $3.67 earnings per share. On average, sell-side analysts anticipate that Vertex Pharmaceuticals Incorporated will post -1.9 EPS for the current fiscal year.

About Vertex Pharmaceuticals

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.